Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!

The goal of this novel clinical trial is to study if drospirenone can work to prevent LH surge in controlled ovarian stimulation in PCOS cases undergoing ART cycles in comparison to a gold standard drug cetrorelix:

All PCOS cases: 50 case in this novel trial. 25 in each group will be randomized after taking 5 days of ovarian stimulation to either drospirenone tablet/d or cetrorelix injection/d till the day of hCG.

At the day of hCG, lab testing will be done in addition to ultrasound assessment by transvaginal probe. the tests are: progesterone, E2, LH.

Assesment will be done for the number quality of follicles and the number quality of embryos developed, development of OHSS, vitrification/thawing of embryos after 1 month then the clinical and chemical pregnancy rate.

Inclusion criteria

• PCOS was diagnosed according to the Rotterdam consensus criteria (two out of three of the following criteria):

• oligo- or anovulation
• clinical and/or biochemical signs of hyperandrogenism
• polycystic ovaries).
• A diagnosis of congenital adrenal hyperplasia, Cushing's syndrome, androgen-producing tumours, hyperprolactinemia and thyroid dysfunction were all rulled out.

Exclusion criteria

• age 38 years
• basal FSH level 12 mIU/mL
• previous ovarian surgery
• congenital uterine anomaly anomaly, intrauterine adhesion and male partner with non-obstructive azoospermia.